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Tricuspid regurgitation (TR) is a frequent and complex problem, commonly combined with left-sided heart disease, such as mitral regurgi-
tation. Significant TR is associated with increased mortality if left untreated or recurrent after therapy. Tricuspid regurgitation was historic-
ally often disregarded and remained undertreated. Surgery is currently the only Class I Guideline recommended therapy for TR, in the
form of annuloplasty, leaflet repair, or valve replacement. As growing experience of transcatheter therapy in structural heart disease,
many dedicated transcatheter tricuspid repair or replacement devices, which mimic well-established surgical techniques, are currently
under development. Nevertheless, many aspects of TR are little understood, including the disease process, surgical or interventional risk
stratification, and predictors of successful therapy. The optimal treatment timing and the choice of proper surgical or interventional tech-
nique for significant TR remain to be elucidated. In this context, we aim to highlight the current evidence, underline major controversial
issues in this field and present a future roadmap for TR therapy.
...................................................................................................................................................................................................
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Introduction
Tricuspid regurgitation (TR) is commonly detected on echocardiog-
raphy.1 Moderate/severe TR is associated with an increased risk for
cardiac and all-cause mortality.2,3 A recent meta-analysis
demonstrated that moderate/severe TR is associated with a two-fold
increased mortality risk compared with no/mild TR, which seems to
be independent of pulmonary pressures and right heart failure (HF).4
Topilsky et al.5 reported that quantitative measures of TR were asso-
ciated with increased mortality in patients with left ventricular (LV)
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systolic dysfunction. These evidences may push towards an earlier in-
dication of correction of TR.
Tricuspid regurgitation remains undertreated as a result of our lim-
ited understanding of the disease and how to quantify it.6–8 Surgery is
currently the only Class I Guideline Recommended therapy for
TR,9,10 which is most often performed during left-sided heart surgery.
Previous estimates indicate that <1% of patients undergo tricuspid
valve (TV) surgery.11 The operative mortality of isolated TV surgery
could be high due to the late referral, multiple comorbidities, and
right ventricle (RV) remodelling.12,13 Due to the paucity of evidence,
American and European guideline recommendations for the manage-
ment of TR are limited, and the timing for surgical intervention is still
debated.9,10 As the management of valvular heart disease moves to-
wards less invasive surgical and transcatheter therapies, several tech-
niques and devices are applied to the TV.14,15 Nevertheless, many
aspects of TR are little understood. In this context, we aim to high-
light controversial issues and present a future roadmap for TR
therapy.
Pathophysiology of tricuspid
regurgitation and rationale for
therapy
With the growing incidence of atrial fibrillation,16 the use of intracar-
diac devices,17 and the global epidemic of valvular heart disease, the
prevalence of TR is likely to increase.18 Recently, Topilsky et al.19
reported the prevalence of TR (0.55%) in a community setting which
was about one-fourth of all left-sided valve disease and similar to the
prevalence of aortic stenosis. The distribution pattern of TR was pri-
mary in 14.6% and secondary in 85.4% of patients.19 Primary TR
results from primary abnormalities of the TV apparatus and can be
divided into congenital and acquired disease. The latter may include
rheumatic disease, carcinoid disease, infective endocarditis, degenera-
tive, or iatrogenic disease from implantable device lead-induced TV
injury/dysfunction or RV endomyocardial biopsy.20 Secondary TR is
due to annular dilatation (with or without leaflet tethering) or RV
dilatation (typically associated with leaflet tethering), with left-sided
heart disease and/or pulmonary hypertension being the most fre-
quent aetiologies.20,21 The disease process of TR is not fully under-
stood and is likely influenced by the underlying aetiology,
concomitant heart disease, and haemodynamic abnormalities.22 Age,
presence of device leads, mild TR at baseline, and receiving left-sided
valvular surgery (without concomitant TV surgery) have been shown
as predictors of development of significant TR.23
Currently, long-term data on the beneficial effect of isolated surgi-
cal TV therapy compared to medical therapy remains scarce.24
According to data from the National Inpatient Sample files from 2004
to 2013 in the USA, isolated TV surgery was performed in 15% of all
patients who underwent TV surgery, with high in-hospital mortality
rate (8–10%) that has remained unchanged over the 10-year
period.12,13 This suboptimal outcome is likely related to comorbid-
ities and referral timing rather than to the risk of isolated TV sur-
gery.25,26 Furthermore, residual or late significant TR after mitral
valve replacement is independently associated with poor outcome.27
Adding TV repair during left-sided heart surgery did not increase
surgical risk and could result in reverse RV remodelling with reduc-
tion of symptoms.28–30 Therefore, a more aggressive approach to
correct concomitant TR in the presence of annular dilatation may re-
duce the chance of late TR progression after left-sided valve surgery.
Specific anatomical
considerations interfering with
tricuspid valve
The TV is a complex apparatus consisting of leaflets, tricuspid annu-
lus, tendinous cords, papillary muscles, and the associated RV. The
normal tricuspid annulus is a saddle-shaped ellipsoid surrounded by
several critical anatomical structures, including the atrioventricular
node, right coronary artery, coronary sinus ostium, and non-
coronary sinus of Valsalva (Figure 1A). Multiple TV structural abnor-
malities may be encountered as a result of different aetiologies with
various morphological changes. Tricuspid annulus dilation, right
atrium/RV dilation, and leaflet malcoaptation are the most common
changes in secondary TR. When tricuspid annulus dilation occurs, its
shape becomes more circular and planar (Figure 1B).31,32 It is usually
observed in the anatomical location of anterolateral free wall and
posterior border. Leaflet malcoaptation may occur due to inadequate
leaflet length to cover the dilated annulus, or in the absence of ad-
equate chordal redundancy resulting in leaflet tethering. The region
of malcoaptation occurs often centrally or extends from the antero-
septal commissure towards the posteroseptal commissure.32,33
Guideline recommendations for
tricuspid regurgitation therapy
Tricuspid regurgitation often presents as a component of a complex
heart disease and its clinical manifestations range from subtle symp-
toms to advanced HF with multiorgan involvement. At the far end of
the disease spectrum, there may be a point of no return where irre-
versible RV dysfunction persists regardless of therapy. Therefore, a
timely therapy is essential to avoid worsening of causative pathology
and the onset of complications caused by TR. However, the indica-
tion and optimal timing of surgery remain controversial due to insuffi-
cient evidence.
The comparison of the American32 and the European guidelines9
for the management of TR is provided in the Supplementary material
online, Table S1. In both guidelines, most of the Classes I and IIa indi-
cations for intervening on significant TR require concomitant left-
sided valve surgery. Isolated TV surgery is recommended in patients
with severe TR who are either symptomatic or are developing pro-
gressive RV dilatation/dysfunction.9 Nevertheless, patients with se-
vere TR are often asymptomatic for a long period of time and
symptoms are not specific, contributing to late referral for surgery.34
Recently, an extended five-stage classification of secondary TR was
proposed to help categorize the severity of disease presenting late in
the disease process.15 Symptoms, severity of TR, leaflet coaptation,
tethering, annular remodelling, and RV function need to be evaluated
to determine the timing and options of treatment.
Tricuspid valve therapy: expert opinion 1933
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..On the other hand, the ‘optimal medical treatment’ has not yet
been defined for right-sided HF. Recently, the American Heart
Association released a scientific statement on evaluation and manage-
ment of right-sided HF.35 Based on the document, medical treatment
of right-sided HF should focus on volume management (diuretics and
renal replacement therapies), afterload reduction (pulmonary vasodi-
lators) and, if needed, mechanical circulatory support.
Risk stratification and heart team
decision-making
In the past decades several models were developed to predict out-
come in cardiac surgery.36 Nevertheless, until recently, no specific
risk model addressed isolated TV surgery. LaPar et al.37 used the
Society of Thoracic Surgeons (STS) database to develop a risk score
for patients undergoing TV surgery. They included age, sex, stroke,
haemodialysis, LV ejection fraction, chronic lung disease, New York
Heart Association functional class, reoperation, and operative char-
acteristics in their models. Although the authors developed well-
discriminated and calibrated models, they could not include indices
of RV dysfunction and liver dysfunction, because these data were sim-
ply not collected. Testing these models will require large clinical data-
sets, however, datasets like the STS database are currently designed
for the majority of patients (with left-sided valve surgery) and do
not specifically address the right heart.38 Therefore, we propose
a standardized approach and risk stratification process for heart
team decision-making. Our proposed stepwise assessment is as fol-
lows (Take home figure):
Step 1: Patient demographics (age and sex).
Step 2: Clinical symptoms (New York Heart
Association functional class).
Step 3: Comorbidities [stroke, major organ dysfunction
(lung, kidney, and liver)].
Step 4: Cardiac pathological remodelling (TR severity,
local remodelling of TV, RV remodelling, pulmonary
vascular resistance, and left-sided heart disease).
Step 5: Surgical or interventional characteristics (iso-
lated, combined, elective, or emergent).
Step 6: Combining 3R’s (Risk, Reversibility, and
Recurrence) information to allocate patient profiles.
Step 7: Decision-making by the multidisciplinary heart
team to provide appropriate treatment (surgical, min-
imal invasive surgical, transcatheter, pharmacological, or
palliative).
Imaging assessment for tricuspid
regurgitation treatment
Imaging assessment for TR treatment runs in three phases: (i) patient
assessment for decision-making; (ii) peri-operative/peri-interven
tional planning and guidance; and (iii) assessing therapeutic efficacy
and durability during follow-up.
Imaging for decision-making in patients
with tricuspid regurgitation
A stepwise approach using multimodality imaging to assessment of
TR is shown in Table 1. First, determining the presence of TR, as well
as the TV morphology and aetiology. Second is to evaluate TR sever-
ity. Third is to assess the haemodynamic impact in terms of regurgi-
tant volume and coexisting pressure overload. Fourth is to identify
the presence (and severity) of associated left-sided heart disease.
Finally, to assess the presence (and severity) of RV remodelling. Two-
dimensional echocardiography, including tissue Doppler imaging and
RV strain, is currently the most widely used imaging modality
(Table 2). Three-dimensional techniques such as three-dimensional
echocardiography, cardiovascular magnetic resonance, or multislice
computed tomography are powerful tools for assessing the TV annu-
lus, as well as the RV and LV size and global function.39
The current echocardiographic criteria for grading TR only con-
sider three grades of severity: mild, moderate, and severe.40 In the
SCOUT trial,41 despite the severity of TR reduced from ‘severe’ to
‘severe’, the equivalent quantitative reduction of a ‘grade’ of TR was
associated with an increase in stroke volume and improved quality of
Figure 1 Anatomical structure of the tricuspid valve. (A) Normal and (B) dilated tricuspid annulus.
1934 C.C. Chang et al.
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.. life. Therefore, an extended five-grade scale of ‘mild, moderate, se-
vere, massive, and torrential’ has been proposed to accommodate
the large variability amongst patients with severe TR.42 Moreover, re-
cent publications have shown that the current cut-off values for quan-
titative parameters used to assess TR severity are inadequate to
quantify the burden on the RV and it is likely that lower threshold val-
ues of effective regurgitant orifice area (EROA) and regurgitant vol-
ume define severe TR.43 This finding was also supported by the study
of Bartko et al.44 showing a significant increase in mortality and
morbidity for EROA >_0.2 cm2 and regurgitant volume >_20 mL in
HF patients with reduced ejection fraction. This may potentially
impact the therapeutic decision-making, particularly timing for
intervention.
Imaging for peri-operative/peri-
interventional planning and guidance
Transthoracic echocardiography (TTE) supported by transoeso-
phageal echocardiography (TOE) is the main tool for preplanning.
For transcatheter therapy targeting the leaflets such as edge-to-
edge repair, TOE, particularly using transgastric views is essential
for assessment of leaflet morphology, coaptation gap, device land-
ing zones and location of main TR jet. Transoesophageal echocar-
diography guides procedural planning and allows for outcome
prediction.45 For annuloplasty devices, intracardiac echocardiog-
raphy may be an alternative,46 especially when TOE images are
suboptimal.
Multislice computed tomography could aid in TV preplanning for
transcatheter therapies mimicking surgical annuloplasty, spacer devi-
ces, and transcatheter TV replacement.47 It allows for accurate meas-
urement of the TV annulus, device landing zone, relationship
between the annulus and right coronary artery, annular tissue quan-
tity and quality, and access selection and guidance.48
.................................................................................................
Table 1 Five-stepwise approach for evaluations of
patients with suspected or established tricuspid
regurgitation
Target Imaging modalities needed to
evaluate
Tricuspid valve morphology
(TV annulus dilatation and
leaflet tethering)
TTE and TOE (2DE and 3DE)
TR severity 2DE/3DE with Doppler, CMR if
unclear
Haemodynamic impact 2DE with Doppler
Preload (RV filling) 2DE and M-mode for longitudinal
function
Afterload (pulmonary
atrial pressure and pul-
monary vascular
resistance)
3DE for RV volumes
RV size and function
Left-sided heart disease 2DE/3DE
Right heart remodelling and
function
Ideally 3D modality for RV size and
function
CMR or 4D MSCT or 3DE > 2DE
3DE >> 2DE
For preclinical studies and first-in-man
studies or small efficacy studies,
CMR and 4D CT may be appropri-
ate. For Large studies and routine
care, 3DE is good alternative
2DE, two-dimensional echocardiography; 3DE, three-dimensional echocardiog-
raphy; CMR, cardiovascular magnetic resonance; MSCT, multislice computed
tomography; RV, right ventricle; TOE, transoesophageal echocardiography; TR,
tricuspid regurgitation; TTE, transthoracic echocardiogram.
Take home figure Heart team decision-making for treatment of tricuspid regurgitation. COPD, chronic obstructive pulmonary disease;
NYHA, New York Heart Association; RV, right ventricle; TR, tricuspid regurgitation; TTVI, transcatheter tricuspid valve intervention.
Tricuspid valve therapy: expert opinion 1935
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..Imaging of therapeutic efficacy and
durability
Surgical success of TV repair is defined, by imaging in the immedi-
ate post-operative period as reduction in TR severity to mild or
less and reduction of TV annulus diameter. In the long run, reverse
RV remodelling, if present, as well as reduction of the RV afterload,
are important imaging endpoints. These are correlated to patients’
symptomatic and functional improvement. In contrast, the need
for reintervention or mortality is the main clinical endpoints
reflecting failure of repair. Ideally, the imaging results of successful
transcatheter repair should match those of surgical repair.
However, most candidates for transcatheter TV repair are cur-
rently patients with advanced RV dysfunction and are often beyond
the point of complete repair.
Tricuspid regurgitation therapy—
surgical perspective
Tricuspid valve repair (annulus, leaflets,
and sub-valvular apparatus)
In the setting of secondary TR with primarily annular dilation, a
reduction annuloplasty is the most commonly used surgical ap-
proach. Now, almost abandoned, the first suture annuloplasty
was described by Kay et al.49 This ‘bicuspidization’ technique is
done by tightening a suture from the anteroposterior commis-
sure to the posteroseptal commissure (Figure 2).49 The second
technique was described by De Vega et al.50 It consists of two
parallel lines of running sutures starting at the posteroseptal
commissure at the annulus level. The suture follows the annulus
with a stitch approximately every 5 mm to the fibrous trigone.
Thereafter, a pledget is placed and the suture is reversed.50
Nowadays, TV annuloplasty using a rigid ring is the most often
applied technique, which provides a lower recurrent rate of sig-
nificant TR compared to suture or flexible ring annuloplasty.51,52
However, the use of a rigid ring was associated with an increased
risk of early ring dehiscence.53 Ideally, a ring annuloplasty should
meet the following criteria: (i) restoring the three-dimensional
shape of the annulus to reduce leaflet stress and tethering; (ii)
addressing the remodelling along the RV free wall and also be
‘open’ at the septal leaflet sector to protect the conduction sys-
tem; and (iii) being flexible to maintain annular dynamicity and
prevent ring dehiscence.54,55
In case of severe leaflet tethering, an annuloplasty alone is usually
not sufficient to ensure adequate repair.56 Dreyfus et al.57 described
an anterior leaflet augmentation technique to address the tethering.
An edge-to-edge technique similar to the Alfieri stitch in mitral valve
repair has been performed resulting in a triple ‘clover-like’ orifice.58
In addition, several case reports exist on neochordae repair of the
TV.59,60 Various other repair techniques specifically addressing a pri-
mary cause (e.g. Ebstein anomaly or endocarditis) are reported in
literature.61,62
Tricuspid valve replacement
Tricuspid valve replacement is usually reserved for patients with
primary TV disease. Nevertheless, the latest consensus is that
patients with severe RV dysfunction, very large annulus, or severe
tethering may be better served with TV replacement.63 A recent
meta-analysis showed comparable outcomes in terms of survival,
reoperation, and prosthetic valve failure after TV replacement be-
tween biological and mechanical valves. Nonetheless, mechanical
prostheses had a higher risk of thrombosis.64 These results were
derived from observational and retrospective studies. Randomized
studies are needed to determine which type of valve is better
for TV replacement. Currently, biological prostheses are preferred
and offer an option for future transcatheter valve-in-valve
implantation.
....................................................................................................................................................................................................................
Table 2 Advantages and limitations of imaging modalities in TR assessment
Imaging technique Main advantages Main limitations
2DE Real-time, versatile, high frame rate Insufficient for 3D complex structures such as TV annulus,
LV, and RV size and function
3DE Both simultaneous multi-plane imaging and real-time 3D
imaging. 3DE is an excellent tool for quantification of ven-
tricular volume and function
Lower frame rate than in 2DE, currently less spatial reso-
lution compared to 2DE, inability to assess tissue charac-
terization such as calcifications or fibrosis
TOE (2DE and 3DE) Real-time intra-procedural planning and guidance Four levels of imaging allow a comprehensive evaluation of
the valve: mid-oesophageal, deep-oesophageal, transgas-
tric, and deep-transgastric
CMR TV severity, perfusion, fibrosis, tissue characterization, and
chamber quantification
Less versatile
MSCT Superb resolution, calcification, excellent tool for TV annu-
lus and preplanning, best to assess radiopaque surgical,
and percutaneous implants
Radiation and less versatile
2DE, two-dimensional echocardiography; 3DE, three-dimensional echocardiography; CMR, cardiovascular magnetic resonance; LV, left ventricle; MSCT, multislice computed
tomography; RV, right ventricle; TOE, transoesophageal echocardiography; TV, tricuspid valve.
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Surgical controversies
The best timing of surgery in patients with TR remains in question.
Repairing the TV in patients with a dilated tricuspid annulus (intrao-
perative >_70 mm, TTE >_40 mm) without significant TR during left-
sided heart surgery has been debated65 since 2005 when this concept
was initially presented by Dreyfus et al.28 This debate is partly fuelled
by the lack of evidence for the validity of the conversion of 70 mm as
measured intraoperatively to 40 mm on TTE.66 Furthermore, since
the TV annulus is not planar, even small variations in the ultrasound
beam plane may result in substantial differences in the measure-
ment.67 The question as to whether repairing a TV with dilated
annulus in patients with trace or mild TR at the time of planned
mitral valve surgery could improve clinical outcomes will be explored
in an ongoing randomized trial (ClinicalTrials.gov identifier:
NCT02675244).
As for patients with late or recurrent significant TR after previous
left-sided surgery, current guidelines consider this is a Class IIa indica-
tion for TV surgery. Yet it has been shown that reoperation on the
TV may be associated with a high mortality.68,69 In combination with
multiple co-existing comorbidities or old age, many surgeons are re-
luctant to operate on these patients, especially if pulmonary hyper-
tension or RV failure is present.27
Predictors of a successful surgical
tricuspid valve repair
From the surgical perspectives, a successful TV repair is mild or less
TR after surgery. Several studies aimed to identify predictors for re-
current TR after surgery (Table 3). Most studies found severe TR and
suture annuloplasty are risk factors of recurrent TR after TV repair.
Nevertheless, these studies use survival analyses in the context of
repeated measures, which is not the preferred approach.78 Navia et
al.79 used advanced statistical modelling for repeated echocardiog-
raphy and showed a higher grade of TR, larger TV annuloplasty ring,
presence of pacemaker leads, mitral valve replacement rather than
repair, depressed LV function, and advanced LV remodelling to pre-
dict TR recurrence. As far as TV morphology is concerned, the
Figure 2 Surgical and transcatheter treatments for tricuspid regurgitation. Direct suture annuloplasty: TrialignTM (Mitralign Inc., Tewksbury, MA,
USA), TriCinchTM (4Tech Cardio Ltd., Galway, Ireland), MIATM (Micro Interventional Devices Inc., Newtown, PA, USA), pledget-assisted suture tri-
cuspid valve annuloplasty (PASTA). Ring annuloplasty: Cardioband (Edwards Lifesciences, Irvine, CA, USA), IRIS (Millipede Inc., Santa Rosa, CA,
USA), DaVingi (Cardiac Implants Ltd, Israel). Coaptation enhancement: edge-to-edge with MitraClipVR (Abbott Vascular, Santa Clara, CA, USA),
PASCAL (Edwards Lifesciences), FORMA (Edwards Lifesciences). Valve replacement: NaviGate (NaviGate Cardiac Structures, Inc., Lake Forest, CA,
USA), Lux (Ningbo Jenscare Biotechnology Co., Ltd., Ningbo, China), Trisol (Trisol Medical, Haifa, Israel), TRiCares (TRiCares SAS, Paris, France),
TricValveVR (P&F Products & Features GmbH, Vienna, Austria), TricentoVR (NVT GmbH, Hechingen, Germany and NVT AG, Muri, Switzerland).
Tricuspid valve therapy: expert opinion 1937
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tethering distance was found to predict recurrent TR after annulo-
plasty.56 As tethering is usually present among inoperable patients
who might be the first target population of transcatheter therapy, the
question whether a transcatheter annuloplasty alone will be sufficient
need to be answered.
Tricuspid regurgitation therapy—
interventional perspective
Following the success of transcatheter aortic valve therapy, there is a
large interest in developing transcatheter TV devices. Multiple novel
technologies are currently invented for transcatheter TV therapy.
Most of these devices are yet in the preclinical or early clinical
assessment.14
Patient selection
The number of patients treated within these transcatheter TV ther-
apy pilot studies is still limited, and most enrolled patients are inoper-
able or at ‘high surgical risk’ with chronic secondary TR
(Supplementary material online, Table S2). Considering the heter-
ogenous nature of TR, patient selection by a multidisciplinary heart
team is paramount to optimize clinical results and effectiveness of
transcatheter TV therapy. We summarized potential target popula-
tion for future studies investigating whether those patients would
benefit from TV interventions (Supplementary material online, Table
S3).80 As to patients with primary TR, there are only few case reports
and some patients with primary TR within TriValve registry.81 There
is insufficient evidence regarding feasibility of transcatheter interven-
tion in this heterogeneous population. An individualized approach is
mandatory.
Anatomical challenges
The most common anatomical changes in significant TR are annulus
dilatation and leaflet tethering. Specific anatomical considerations
should be assessed according to different therapeutic targets. We
summarize the potential anatomical and pathophysiological con-
straints of transcatheter TV interventions.
(1) Challenges during catheter navigation
a. The angulation between the annular plane and the superior and in-
ferior venae cava complicates the transvenous access.
b. The loss of anatomical landmarks under pathologic conditions
(right atrial and ventricular dilation) complicates catheter naviga-
tion and interferes with proper positioning of repair/replacement
devices.
c. Pre-existing device leads could interfere with device delivery and
deployment.
d. Imaging views and quality, which depends on numerous patient
characteristics (i.e. mechanical valves in place, chest deformation,
oesophageal anatomy/pathologies) but also on the device used for
repair.
(2) Difficultly in proper sizing
a. Tricuspid annulus is significantly larger than other valves and is
influenced by volume status which might preclude appropriate siz-
ing and device selection.
b. Flexibility and fragility of the annulus and the surrounding myocar-
dium counteracts fixation and long-term stability of transcatheter
TV replacement devices.
(3) Increased risk of thrombosis
a. The low pressure and slow flow in the right heart chambers might
provoke device thrombosis.
Approaches for transcatheter tricuspid
valve interventions
As shown in Figure 2, most of devices for transcatheter TV therapy
are designed to mimic surgical techniques. Currently, the most widely
used technique is the edge-to-edge repair using the MitraClip device
(Abbott, Santa Clara, CA, USA) in TV position to improve leaflet co-
aptation.82 Nevertheless, transcatheter repair cannot replace all the
types of surgical repair, and several vendors are currently developing
transcatheter heart valves for TV replacement. Despite the growing
experience in transcatheter TV interventions, we would like to
.............................................................................................................................................................................
....................................................................................................................................................................................................................
Table 3 Risk factors of recurrent tricuspid regurgitation
Risk factors
Study De Vega vs. ring
annuloplasty
HR (95% CI)
Severe TR at
baseline
HR (95% CI)
Higher PASP
HR (95% CI)
Female gender
HR (95% CI)
Atrial fibrillation
HR (95% CI)
Ren (2015)70 1.47 (1.0–1.9) NS 1.54 (1.1–2.0) NS —
Lin (2014)71 7.2 (2.7–15.4) 3.6 (1.7–12.1) NS NS 9.4 (2.3–94.0)
Ratschiller (2015)72 — 3.0 (1.2–7.8) — 2.5 (1.0–5.9) 4.3 (1.0–18.3)
Gatti (2016)73 2.2 (1.1–4.3) 1.2 (0, 6–2.4) 1.3 (0.6–2.9) — —
Yoda (2011)74 — 8.23a NS — NS
Jung (2010)75 — — — — NS
Murashita (2014)76 10.7 (3.7–31.0)b 2.8 (1.4–5.7)b — — —
Ghanta (2007)77 0.64 (0.1–1.2)c 4.0 (3.4–4.7) 1.0 (0.9–1.0) — —
—, not reported; CI, confidence interval; HR, hazard ratio; NS, not significant upon univariate analyses; PASP, pulmonary arterial systolic pressure; TR, tricuspid regurgitation.
aNo confidence interval reported.
bOnly univariable cox regression model.
cKay vs. Ring annuloplasty.
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emphasize that clinical data on most of the devices are not sufficient
to conclude on their safety and efficacy. When evaluating these early
clinical data, the following issues should be addressed:
(1) Patients enrolled in first-in-man studies differ markedly in terms of
TR severity, EROA, vena contracta area, with some studies focusing
on severe TR as compared to torrential TR. This has to be consid-
ered when efficacy in TR reduction and potential for clinical
improvements of different devices/approaches are assessed.
(2) General application and comparison between studies are hindered
by the differences in study design.
(3) Clinical and echocardiographic endpoints, device and procedural
success, and optimal TR reduction should be clearly defined.
(4) Most of the surgical data on the TV are derived from patients who
underwent left-sided heart surgery which is not fully transferable to
dedicated transcatheter interventions.
Lessons learnt from transcatheter
left-sided valve therapy
Aortic valve
Transcatheter aortic valve replacement has been an established first-
line therapy for high-risk and could be an alternative therapy for sur-
gery in patients with aortic stenosis and intermediate and more re-
cently low risk.83,84 With the progress of transcatheter valve therapy,
balloon-expandable transcatheter heart valves, which were designed
for the aortic position are now being applied for degenerated bio-
prostheses in TV position.85,86 Off-label heterotopic heart valve im-
plantation in the superior/inferior vena cava (preferred is one valve in
the inferior vena cava) is currently being tested in patients who are in-
operable or at very high surgical risk for TV replacement.87,88
Furthermore, dedicated orthotopic/heterotopic devices for TR are
in development.89 Navia et al.90 reported the first-in-man results of
the NaviGate valve. Several patients received this bioprothesis with
excellent TR reduction.91 Conduction disturbances requiring pace-
maker implantation has been reported in one patient.14 Tricuspid
valve surgery carries a significant risk of conduction disorders requir-
ing permanent pacemaker implantation.92 Whether transcatheter TV
therapy, particular annuloplasty, and valve replacement, would en-
counter similar issues is yet unknown.
Mitral valve
Transcatheter therapy for severe functional mitral regurgitation
(FMR) associated with HF has increased rapidly recently. Results of
two clinical outcome trials, MITRA-FR and COAPT were pub-
lished.93,94 Both trials randomly assigned patients with FMR to
MitraClip plus guideline-directed optimal medical treatment
(GDMT) or GDMT only. MITRA-FR failed to demonstrate the bene-
fit of MitraClip procedure in terms of a composite endpoint (all-cause
death or unplanned hospitalization for HF). Conversely, the COAPT
trial showed that the MitraClip procedure significantly reduced HF
rehospitalizations and all-cause death during 2-year follow-up. The
COAPT trial applied a prespecified approach by a group of HF spe-
cialists to evaluate GDMT prior to randomization, and therefore, this
trial had a long enrolment period. The conflicting results of the two
studies reflect the importance of patient selection before irreversible
HF ensues, optimization of medical therapy and the role of a
multidisciplinary heart team. The MitraClip device has been applied
to the tricuspid position. The feasibility and safety of edge-to-edge
TV repair using the MitraClip device has been reported.45,81
The Cardioband system (Edwards Lifesciences, Irvine, CA, USA) is
a transcatheter direct annuloplasty device that mimics surgical repair.
The feasibility study in symptomatic patients with FMR demonstrated
that Cardioband implantation was effective in reducing mitral regurgi-
tation and was associated with improvement in HF symptoms.95 The
ACTIVE randomized trial is ongoing to compare Cardioband im-
plantation plus GDMT to GDMT alone in patients with significant
FMR (ClinicalTrials.gov identifier: NCT03016975). The tricuspid
Cardioband device has CE mark approval and is the first commercial-
ly available transcatheter device for the treatment of significant TR. In
the TRI-REPAIR study, Cardioband implantation provided favourable
clinical and functional outcomes at 6 months.96
Nevertheless, how to define an optimal repair is still an unsolved
issue. In the recent published mid-term outcomes of TriValve registry
including 312 patients with severe TR,82 procedural success (defined
as patient alive at the end of the procedure, with the device success-
fully implanted and delivery system retrieved, with a residual TR
grade <_2 by the investigators) was achieved in 72.8% of patients and
was independently associated with increased mortality. The definition
of successful repair remains discrepant across studies investigating
transcatheter devices (Supplementary material online, Table S4). In
order to adequately compare clinical outcomes after surgical or
transcatheter therapy, definitions of clinical endpoints including tech-
nical, device, procedural as well as patient success should be refined
and standardized in future studies.
Conclusions
With the development of transcatheter therapy, there has been an
increasing focus on the treatment of significant TR. Although early
safety and efficacy results of transcatheter TV therapy are encourag-
ing, remaining uncertainties including grade of TR severity (quantita-
tive and qualitative), patient selection, risk stratification, timing of
intervention, and definition of successful repair warrant further inves-
tigations. Due to the complex nature and interaction between TR
and HF, the question as to whether a timely transcatheter TV ther-
apy, a minimal invasive intervention, may change the disease process
and improve clinical outcomes remains to be answered in prospect-
ive studies. This manuscript uses a novel heart-team approach via a
comprehensive and a balanced focus on uncertainties, controversies,
step-by-step recommendations, and endpoints definitions in TR ther-
apy. Therefore, it provides a framework for randomized clinical trials
and registries in the field of transcatheter TV therapy. Since there is
no document on the Tricuspid Valve Academic Research
Consortium yet, we believe that this work will pave the road as the
foundation for such a needed document.
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Supplementary material is available at European Heart Journal online.
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